SS
Stephen Squinto
Morgan Life Sciences Private Capital at J.P. Morgan Asset Management
New York, New York
Overview
Stephen Squinto is a Chief Investment Officer with a strong background in life sciences and biotechnology, having held leadership roles at companies like Alexion Pharmaceuticals and Regeneron Pharmaceuticals. He has successfully invested in various companies at different stages, including Enlaza Therapeutics and Audentes Therapeutics.
Currently, Stephen serves as the Chief Investment Officer at J.P. Morgan Asset Management, specializing in investments in pharmaceuticals and biotech sectors, with a focus on companies in New York City.
Work Experience
Chief Investment Officer, JP Morgan Life Sciences Private Capital
2022 - Current
Executive Chairman
2021 - 2022
Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.
Raised $41,000,000.00 from CureDuchenne Ventures, OrbiMed, Logos Capital and Surveyor Capital.
Executive Partner
2019 - 2022
Venture Partner
2015 - 2019
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals for medical devices and diagnostics.
Executive Partner
2019 - 2022
Co-Founder; Exec VP, Head of R&D
1992 - 2015
Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.
Raised $5,800,000.00.
Senior Leadership, Early Company Builder
1988 - 1992
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Raised $15,931,980.00 from U.S. Department of Health & Human Services.